Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
May 08  •  04:00PM ET
3.52
Dollar change
+0.29
Percentage change
8.98
%
May 08, 2:27 PMNephros posts record Q1 2026 revenue $5.2M (+7% YoY) as gross margin drops to 57% on tariffs, mix
Index
-
P/E
49.79
EPS (ttm)
0.07
Insider Own
13.10%
Shs Outstand
10.84M
Perf Week
13.18%
Market Cap
38.22M
Forward P/E
35.20
EPS next Y
0.10
Insider Trans
0.00%
Shs Float
9.43M
Perf Month
20.96%
Enterprise Value
35.17M
PEG
-
EPS next Q
-0.01
Inst Own
48.80%
Perf Quarter
-9.04%
Income
0.78M
P/S
2.00
EPS this Y
-58.23%
Inst Trans
1.82%
Perf Half Y
-38.14%
Sales
19.12M
P/B
3.57
EPS next Y
117.63%
ROA
6.07%
Perf YTD
-27.87%
Book/sh
0.99
P/C
9.51
EPS next 5Y
-
ROE
7.76%
52W High
6.42 -45.17%
Perf Year
76.88%
Cash/sh
0.37
P/FCF
23.16
EPS past 3/5Y
- -
ROIC
6.89%
52W Low
1.88 87.73%
Perf 3Y
136.24%
Dividend Est.
-
EV/EBITDA
43.42
Sales past 3/5Y
23.50% 17.02%
Gross Margin
59.27%
Volatility
12.80% 9.23%
Perf 5Y
-52.36%
Dividend TTM
-
EV/Sales
1.84
EPS Y/Y TTM
1531.88%
Oper. Margin
3.54%
ATR (14)
0.28
Perf 10Y
24.16%
Dividend Ex-Date
-
Quick Ratio
3.12
Sales Y/Y TTM
23.25%
Profit Margin
4.06%
RSI (14)
64.33
Dividend Gr. 3/5Y
- -
Current Ratio
4.55
EPS Q/Q
-75.86%
SMA20
14.43%
Beta
1.48
Payout
0.00%
Debt/Eq
0.09
Sales Q/Q
6.87%
SMA50
9.87%
Rel Volume
3.33
Prev Close
3.23
Employees
36
LT Debt/Eq
0.05
SMA200
-16.58%
Avg Volume
37.49K
Price
3.52
IPO
Sep 21, 2004
Option/Short
No / Yes
Trades
Volume
124,939
Change
8.98%
Date Action Analyst Rating Change Price Target Change
Jan-26-21Initiated B. Riley Securities Buy $12.50
May-08-26 08:30AM
May-07-26 04:05PM
Apr-30-26 04:00PM
Apr-16-26 09:57AM
Apr-01-26 09:00AM
09:02PM Loading…
Mar-13-26 09:02PM
08:30AM
Mar-12-26 04:10PM
Mar-05-26 07:04AM
Feb-13-26 08:16AM
Dec-11-25 09:00AM
Nov-10-25 08:04PM
Nov-06-25 04:10PM
Oct-30-25 04:00PM
Oct-08-25 09:00AM
10:41AM Loading…
Oct-07-25 10:41AM
Aug-08-25 11:00PM
Aug-07-25 04:00PM
Jul-31-25 04:00PM
Jul-15-25 09:19AM
May-28-25 09:00AM
May-08-25 04:00PM
May-07-25 11:46AM
Apr-30-25 04:00PM
Apr-28-25 09:00AM
Mar-06-25 04:00PM
Mar-05-25 07:36AM
Feb-26-25 04:00PM
Dec-04-24 09:00AM
Nov-08-24 04:03PM
04:01PM Loading…
Nov-07-24 04:01PM
Nov-06-24 07:56AM
Oct-31-24 07:30AM
Oct-25-24 09:10AM
Oct-24-24 09:00AM
Oct-17-24 09:00AM
Oct-09-24 05:56PM
Aug-08-24 04:01PM
Aug-01-24 07:30AM
May-09-24 04:15PM
May-02-24 07:30AM
Apr-29-24 09:00AM
Apr-23-24 07:30AM
Mar-08-24 01:01PM
Mar-07-24 04:15PM
Feb-29-24 04:30PM
Nov-11-23 12:41PM
Nov-08-23 04:15PM
Nov-01-23 07:30AM
Oct-25-23 07:30AM
Sep-19-23 04:30PM
Aug-09-23 04:15PM
Jul-26-23 07:30AM
May-24-23 07:30AM
May-10-23 04:15PM
May-08-23 07:30AM
Apr-26-23 07:30AM
Apr-04-23 07:30AM
Mar-08-23 04:15PM
Mar-01-23 04:30PM
Feb-22-23 04:30PM
Jan-11-23 07:30AM
Nov-02-22 04:15PM
Oct-19-22 07:30AM
Oct-12-22 07:30AM
Oct-11-22 07:30AM
Sep-28-22 07:30AM
Sep-08-22 04:00PM
Aug-13-22 08:22AM
Aug-10-22 04:15PM
Jul-27-22 07:30AM
Jul-06-22 07:30AM
May-17-22 07:30AM
May-04-22 04:15PM
Apr-27-22 07:30AM
Apr-26-22 07:30AM
Mar-21-22 07:30AM
Feb-28-22 07:30AM
Feb-23-22 04:15PM
Feb-09-22 07:30AM
Jan-13-22 07:30AM
Jan-11-22 07:30AM
Nov-23-21 04:15PM
Nov-08-21 07:30AM
Nov-04-21 04:15PM
Oct-21-21 07:30AM
Oct-08-21 07:30AM
Oct-05-21 07:30AM
Sep-15-21 09:39AM
Sep-06-21 11:42AM
Sep-01-21 07:30AM
Aug-05-21 04:15PM
Jul-28-21 03:03PM
Jul-12-21 07:30AM
Jul-09-21 04:18PM
Jul-08-21 11:20AM
07:30AM
05:07AM
Jun-29-21 08:50AM
Jun-23-21 09:35AM
Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration, Pathogen Detection and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Pathogen Detection segment develops and sells portable, real-time water testing systems designed to provide actionable data on waterborne pathogens in approximately one hour. The Renal Products segment consists of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate, and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Banks Robert R. Jr.President and CEOMar 23 '26Option Exercise1.44120,000172,800190,000Mar 25 04:54 PM
Krandel JudyChief Financial OfficerMar 23 '26Option Exercise1.7168,861117,75268,861Mar 25 04:53 PM